000516 Xi'An International Medical Investment
- 5.67
- -0.27-4.55%
Xi'An International Medical Investment News
International Medicine: third quarter report 2024
xi'an international medical investment (000516.SZ): a net loss of 0.212 billion yuan in the first three quarters.
GeLongHui on October 24th, xi'an international medical investment (000516.SZ) announced its third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.606 billion yuan, a year-on-year increase of 7.85%; net income attributable to shareholders of the listed company was a loss of 0.212 billion yuan, a year-on-year increase of 4.59%; net income after deducting non-recurring gains and losses was a loss of 0.22 billion yuan, a year-on-year increase of 37.20%; basic earnings per share was -0.0954 yuan per share.
Obesity affects employment, eli lilly and co will try to use weight loss drugs to address the issue of unemployment in the united kingdom.
Peking time on the evening of the 15th, usa pharmaceutical giant eli lilly and co signed a major investment agreement with the united kingdom to explore the use of weight-loss drugs to curb unemployment. The weight-loss treatment company and the developer of the Zepbound drug announced on Monday that it will invest 0.279 billion british pounds (approximately 0.364 billion us dollars) to help address a major health challenge in the united kingdom—obesity, of course, being among them. The strategic cooperation between eli lilly and co and the UK Department of Health and Social Care (DHSC) and the Department of Science, Innovation and Technology (DSIT) is the first.
xi'an international medical investment (000516.SZ): accumulated repurchase of 0.4865% of the company's shares.
Gelonghui October 8 | xi'an international medical investment (000516.SZ) announced that as of September 30, 2024, the company has cumulatively repurchased 10,997,100 shares of the company through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.4865% of the company's current total share capital, with a highest fill price of 5.618 yuan/share, a lowest fill price of 4.61 yuan/share, and a total fill amount of 57,426,831.72 yuan (excluding transaction costs).
xi'an international medical investment (000516.SZ): the planned number of beds in its medical institutions is 10,137.
On September 30, Gelonhui reported that xi'an international medical investment (000516.SZ) stated on the investor interaction platform that the planned number of beds in the company's medical institutions is 10,137. Recently, Xi'an Gaoxin Hospital had an average daily inpatient bed usage of about 1500-1600 beds; Xi'an International Medical Center Hospital North and South regions had an average daily inpatient bed usage of about 3400-3500 beds.
International Medicine: 2024 Semi-Annual Report Summary
International Medicine: Semi-Annual Report 2024
Xi'an International Medical Investment (000516.SZ) released its performance for the first half of the year, with a net loss of 0.173 billion yuan.
xi'an international medical investment (000516.SZ) released the semi-annual report for 2024, with a revenue of 2.42 billion yuan, a year-on-year comparison...
Xi'an International Medical Investment (000516.SZ) has repurchased 0.4865% of its total shares.
Xi'an International Medical Investment (000516.SZ) announced that as of July 31, 2024, the company has repurchased 10,997,100 shares of company stock through the Shenzhen Stock Exchange trading system in a centralized bidding transaction, accounting for 0.4865% of the company's current total share capital. The highest fill price was 5.618 yuan/share and the lowest fill price was 4.61 yuan/share, with a total fill amount of 57,426,831.72 yuan (excluding transaction fees). The progress of the repurchase program complies with relevant laws and regulations and the established share repurchase program of the company.
Xi'An International Medical Investment: 2024 Interim Performance Forecast
Xi'an International Medical Investment (000516.SZ) has spent 57.43 million yuan to repurchase 10.9971 million shares.
Xi'an international medical investment (000516.SZ) announced that as of June 30, 2024, the company has cumulatively passed the Shenzhen...
Xi'an International Medical Center Hospital South and North Campus have an average daily bed occupancy rate of about 3500-3600.
On June 27th, Geelong reported that Xi'an International Medical Investment (000516.SZ) has performed well in recent business operations, with all medical institutions conducting orderly operations and an overall positive growth trend. The average daily hospital bed usage rate for both the north and south campuses of Xi'an International Medical Center is about 3,500-3,600 beds, while for Xi'an Gaoxin Hospital, the average daily hospital bed usage rate is about 1,500-1,600 beds. With increasing patient visits and bed usage rates in their medical institutions, the company is seeing a sustained growth trend in business performance and improved profitability.
International Medicine (000516.SZ): Initial repurchase of 2.3 million shares involving 128.56 million yuan
Gelonghui, May 27丨International Medicine (000516.SZ) announced that on May 27, 2024, for the first time, the company repurchased 2.3 million shares of the company's shares through a dedicated stock repurchase securities account, accounting for 0.1017% of the company's current total share capital. The highest transaction price was 5.62 yuan/share, the lowest transaction price was 5.54 yuan/share, and the total transaction amount was 128.56 million yuan (excluding transaction fees).
Gelonghui Fund Daily | The “magic foundation” strategy for small and micro capitalization stocks is quietly changing!
Focus on the latest fund information
International Medicine (000516.SZ): Affiliated medical institutions use chemotherapy, endocrine therapy, targeted treatment, etc. for common solid tumors
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's medical institutions are characterized by chemotherapy, endocrine therapy, targeted therapy, immunotherapy, malignant tumor radiotherapy, thyroid breast surgery, and intravenous infusion port implantation for chemotherapy patients. Well-known cancer treatment centers and senior experts within the United Nations provide patients with scientific, standardized and individualized diagnosis and treatment plans.
International Medicine (000516.SZ): The main operating costs are medical business costs, including procurement costs of pharmaceuticals and consumables, personnel expenses, depreciation and amortization, etc.
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's main operating costs are medical business costs, including procurement costs of pharmaceuticals and consumables, personnel expenses, depreciation and amortization, etc. In the future, the company will continuously optimize cost control, improve operational efficiency, and promote high-quality development of the company's main medical industry.
International Medicine (000516.SZ): The company's medical institutions have more than 500 items including cell morphology testing centers, immunological testing centers, cytogenetic testing centers, and preventive medicine
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's medical institutions have cell morphology testing centers, immunological testing centers, cytogenetics testing centers, molecular biology testing centers, stem cell and immune cell transformation centers. The testing programs cover more than 500 items such as hematological diagnosis, treatment, prognostic assessment guidance, tumor diagnosis and targeted therapy, pharmacogenomics, and preventive medicine, to protect patients in multiple dimensions and angles.
International Medicine (000516.SZ): Net profit for the first quarter - $105 million
On April 25, Ge Longhui (000516.SZ) released its report for the first quarter of 2024, achieving operating income of 1,173 billion yuan, an increase of 10.75% over the previous year; net profit attributable to shareholders of listed companies - 105 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 898.496 million yuan, basic earnings per share - 0.0464 yuan.
International Medicine (000516.SZ): Chairman, Vice Chairman and all executives increased their holdings by a total of 537,900 shares
Gelonghui, Feb. 2 | International Medicine (000516.SZ) announced that the company received notifications from the chairman, vice chairman and all senior management of the company to learn that the company's chairman, Ms. Shi Jin, Vice Chairman, Ms. Wang Aiping, Director and President Mr. Liu Ruixuan, Director and Vice President, Mr. Sun Wenguo, Vice President and Board Secretary, Mr. Wang Yu, Vice President, Mr. Sun Yikuan, Vice President, and Ms. Wang Yaxing increased the company's shares by centralized bidding through the Shenzhen Stock Exchange trading system from January 31 to February 2, 2024, accounting for Total share capital of the company 2,260
International Medicine (000516.SZ) issued a forecast loss. The net loss for 2023 is expected to be 280 million yuan to 370 million yuan
International Medicine (000516.SZ) announced its 2023 annual results forecast, which is expected to be owned by shareholders of listed companies for the whole year...
Analysis
Price Target
No Data
No Data